[Ethmozine pharmacokinetics in liver insufficiency]

Area of Science:

• Pharmacology
• Hepatology
• Clinical Pharmacy

Background:

• Ethmozine is an antiarrhythmic drug.
• Liver function significantly impacts drug metabolism and clearance.
• Impaired liver function can alter pharmacokinetics, potentially leading to toxicity.

Purpose of the Study:

• To evaluate the risk of ethmozine overdosage in patients with severe liver impairment (Stages II-III).
• To investigate the pharmacokinetic changes of ethmozine in patients with compromised liver function.
• To determine the implications for clinical practice regarding ethmozine dosing in this population.

Main Methods:

• Analysis of ethmozine pharmacokinetics in patients with severe liver dysfunction.
• Assessment of drug biotransformation rates and plasma protein binding.
• Correlation of drug concentrations with observed side effects.

Main Results:

• A high risk of ethmozine overdosage and associated adverse effects (e.g., dry mouth, tinnitus, visual disturbances, nausea, vomiting) was observed.
• Reduced ethmozine biotransformation leads to higher blood concentrations.
• Decreased plasma protein binding increases the free fraction of ethmozine, enhancing its effects and toxicity.

Conclusions:

• Routine ethmozine doses are unsafe for patients with severe liver impairment.
• Pharmacokinetic monitoring of ethmozine is essential in patients with liver dysfunction.
• Dose adjustments are necessary to prevent toxicity and ensure therapeutic efficacy.